# Jiaxing Taimei Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiaxing-taimei-medical-technology-co

- Industry: Software
- Headquarters: Jiaxing, China
- Website: www.taimeitech.com
- Total disclosed funding: $319M
- Latest round: Series F (Sep 28, 2020)
- Investors on record: 19

## About

Founded in 2013 and based in Jiaxing, China, Jiaxing Taimei Medical Technology Co., Ltd. is a medical technology company that focuses on developing digital operation platforms for the life science industry. In September 2020, the firm raised CNY 1.2 billion in series F funding. In October 2024, the company was listed on the Hong Kong Stock Exchange. Its stock code is 02576. As of October 2024, it has obtained ISO20000 Information Technology Service Management System Certification, ISO9001 Quality Management System Certification and ISO27001 Information Security Management System Certification.

The company's main products include the TrialOS pharmaceutical R&D collaboration platform, the eArchives (eTMF) clinical research essential document management system, and the eSitePro clinical research integrated project management platform. eArchives (eTMF) is a clinical research essential document management system that provides full-process services from clinical trial document generation, collection, and approval.

The company’s revenue is generated by providing pharmaceutical R&D collaboration platform and medical software, etc.

In the future, the company will upgrade the PharmaOS platform and expand overseas markets.

## Funding rounds

- Series F, Sep 28, 2020, $177M — SB China Venture Capital, 5Y Capital, YF Capital, Tencent Investment, Hillhouse Investment, Zheshang Venture Capital, Ivy Capital, Co-Win Ventures, MPC, Fanzhuo Capital, GL Ventures, Future Qichuang Capital
- Series E, Oct 18, 2019 — SAIF Partners, SB China Venture Capital, 5Y Capital, Tiger Global Management, Tencent Investment, Zheshang Venture Capital, Ivy Capital, Co-Win Ventures
- Series E, Jan 26, 2019, $80M — SB China Venture Capital, Co-Win Ventures, Tiger Global Mauritius Fund
- Series D, Apr 9, 2018, $48M — SAIF Partners, SB China Venture Capital, 5Y Capital, Zheshang Venture Capital, Ivy Capital, Co-Win Ventures
- Series C, Jan 13, 2017, $14M — NLVC, Genesis Capital, Co-Win Ventures, MPC
- Series B, Jun 21, 2016 — Matrix Partners, NLVC, Oriza Holdings
- Series A, Feb 8, 2016 — Matrix Partners
- Angel, Nov 1, 2014 — Oriza Holdings

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel, Series B
- Matrix Partners (https://capitalatlas.ai/funds/matrix-partners) — Series A, Series B
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B, Series C
- Genesis Capital — Series C
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series C, Series D, Series E, Series F
- MPC — Series C, Series F
- SAIF Partners (https://capitalatlas.ai/funds/saif-partners) — Series D, Series E
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series D, Series E, Series F
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series D, Series E, Series F
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series D, Series E, Series F
- Ivy Capital (https://capitalatlas.ai/funds/ivy-capital) — Series D, Series E, Series F
- Tiger Global Mauritius Fund — Series E
- Tiger Global Management (https://capitalatlas.ai/funds/tiger-global-management) — Series E
- Tencent Investment — Series E, Series F
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series F
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series F
- Fanzhuo Capital — Series F
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series F
- Future Qichuang Capital (https://capitalatlas.ai/funds/future-qichuang-capital) — Series F